GDM and Its Consequences in Mothers and Offsprings (GDMCMO)

September 11, 2023 updated by: Xiu Qiu, Guangzhou Women and Children's Medical Center

Gestational Diabetes Mellitus and Its Consequences in Mothers and Offsprings

Gestational diabetes mellitus (GDM) is one of the most common disorders which occured during pregnancy. GDM is not only associated with short-term maternal and fetal adverse outcomes, but also related to a wide range of long-term consequences for both mother and child. The GDM and Its Consequences for mothers and offsprings (GDMCMO) aims to establish a cohort to follow both maternal and offsprings'short-term and long-term outcomes, including fetal malformations including congenital heart diseases, birth weight, preterm birth, caesarean section delivery, body growth and neurodevelopment after birth, obesity, type 2 diabetes and impaired insulin sensitivity and secretion, lung health and allergic diseases later in life for offspring, as well as future type 2 diabetes and cardiovascular risk factors for mother after delivery. Biological samples including blood and tissue samples of mothers and children are also collected during pregnancy and after delivery.

Study Overview

Detailed Description

Gestational diabetes mellitus (GDM) is one of the most common disorders which occured during pregnancy. GDM is not only associated with short-term maternal and fetal adverse outcomes, but also related to a wide range of long-term consequences for both mother and child. Although maternal hyperglycemia often become normal shortly after pregnancy, women with GDM have crucially increased risk of development of type 2 diabetes later in life and the mechanisms are not fully understand. Systematic follow-up of the outcomes related to GDM would be ideal to observe the nature progression of GDM to diabetes and could help to develop preventable targets for intervention. The risks of obesity, the metabolic syndrome, and type 2 diabetes in offspring of mothers with GDM significantly increased 1-7 folds than those whose mothers didn't have GDM. The underlying pathogenic mechanisms behind the impaired metabolic risk profile and other diseases in offspring are unknown, but environmental changes including epigenetic changes induced by exposure to maternal hyperglycaemia and genetic factors may play essential roles. The GDM and Its Consequences for mothers and offsprings (GDMCMO) aims to establish a cohort to follow both maternal and offsprings'short-term and long-term outcomes, including fetal malformations including congenital heart diseases, birth weight, preterm birth, caesarean section delivery, body growth and neurodevelopment after birth, obesity, type 2 diabetes and impaired insulin sensitivity and secretion, lung health and allergic diseases later in life for offspring, as well as future type 2 diabetes and cardiovascular risk factors for mother after delivery. Biological samples including blood and tissue samples of mothers and children are also collected during pregnancy and after delivery. We also aim to identify the high-risk population of mother-child pairs who are more likely to develop these adverse consequences, which might help to improve precise intervention and resource saving and provide evidence for preventable targets development.

Study Type

Observational

Enrollment (Estimated)

7000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Songying Shen, MSc
  • Phone Number: 0086 20 38367159

Study Contact Backup

Study Locations

    • Guangdong
      • Guangzhou, Guangdong, China, 510623
        • Recruiting
        • Guangzhou Women And Children's Medical Center
        • Contact:
          • Songying Shen, MSc
          • Phone Number: 0086 20 38367159
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Women diagnosed with gestational diabetes mellitus during pregnancy and their offsrpings

Description

Inclusion Criteria:

  1. Pregnant women diagnosed with gestational diabetes mellitus
  2. Pregnant women intended to eventually deliver in Guangzhou Women and Children's Medical Center
  3. Permanent residents or families intended to remain in Guangzhou with their child for no less than 3 years

Exclusion Criteria:

  1. Women with pre-gestational diabetes mellitus
  2. Women with chronic hypertension or kidney disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change of obesity status during childhood and adolescence
Time Frame: At age of 6 months, 1 year, 3 years, 6 years, 12 years and 18 year
Weight in kilograms and height in meters were measured by nurses in clinic using standard tools. Weight and height will be combined to report BMI in kg/m^2. Childhood obesity is defined as a BMI equal to or larger than the 95th percentile for age by sex based on WHO Child Growth Standards.
At age of 6 months, 1 year, 3 years, 6 years, 12 years and 18 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants with adverse pregnancy outcomes
Time Frame: At delivery
Including abortion, stillbirth, live birth, macrosomia, preterm birth, low birth weight, caesarean section delivery, and birth defects.
At delivery
Change of type 2 diabetes status in mothers
Time Frame: At 1 year, 3 years , 6 years, 12 years and 18 year after delivery
Assessed by testing concentrations of maternal blood glucose.
At 1 year, 3 years , 6 years, 12 years and 18 year after delivery
Change of body composition of mothers
Time Frame: At 42 days, 6 months, 1 year, 3 years , 6 years, 12 years and 18 year after delivery
Assessed body composition using dual-energy X-ray absorptiometry.
At 42 days, 6 months, 1 year, 3 years , 6 years, 12 years and 18 year after delivery
Change of depression symptom of mothers
Time Frame: At 1 year, 3 years , 6 years, 12 years and 18 year after delivery
Using Edinburgh Postnatal Depression Scale and Self-rating Depression Scale to assess maternal depression. Higher score is considered more depressive.
At 1 year, 3 years , 6 years, 12 years and 18 year after delivery
Change of neurodevelopment at early childhood
Time Frame: age of 6 weeks, 6 months, 1 year and 3 years.
Assessed by Gesell Developmental Schedules and Ages&Stages Questionnaires which include adaptive, gross motor, fine motor, language, and social function domains. Higher intelligence quotient score in each domain is considered a better outcome. Intelligence quotient of Gesell Developmental Schedules being less than 86 or intelligence quotient of Ages&Stages Questionnaires being no more than -2SD under the mean is defined as suspected development retardation.
age of 6 weeks, 6 months, 1 year and 3 years.
Change of lung function during childhood and adolescence
Time Frame: At age of 6 years, 12 years and 18 years.
Zrs, R5, R20, X5, X20, Fres assessed by impulse oscillometry
At age of 6 years, 12 years and 18 years.
Change of Allergic diseases status during childhood and adolescence
Time Frame: At age of 1 year, 3 years, 6 years, 12 years and 18 years.
Eczema, allergic rhinitis, wheeze, and asthma diagnosed by the doctors or assessed by the standardized questionnaires
At age of 1 year, 3 years, 6 years, 12 years and 18 years.
Change of type 2 diabetes during childhood and adolescence
Time Frame: At age of 6 years, 12 years and 18 years.
Assessed by testing concentrations of children's blood glucose.
At age of 6 years, 12 years and 18 years.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Xiu Qiu, MD,PhD, Guangzhou Women and Children's Medical Center, China

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2012

Primary Completion (Estimated)

December 31, 2038

Study Completion (Estimated)

December 31, 2038

Study Registration Dates

First Submitted

July 20, 2020

First Submitted That Met QC Criteria

August 24, 2020

First Posted (Actual)

August 28, 2020

Study Record Updates

Last Update Posted (Actual)

September 13, 2023

Last Update Submitted That Met QC Criteria

September 11, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Childhood Obesity

3
Subscribe